Cancer News and Research

Latest Cancer News and Research

Animal antibodies help identify diseased cells during immunohistology procedures

We all know it from biology lessons at school: Antibodies help us to ward off disease and are essential components of our immune system. What many people do not know is that physicians and scientists use animal antibodies to identify diseased or mutated cells.

20 Jan 2016

Only 3% of GPs fully confident and informed about pancreatic cancer symptoms

Just 3% of GPs who responded to a recent survey, commissioned by Pancreatic Cancer Action, said they felt fully confident and informed about the symptoms of pancreatic cancer, and the difficulty in recognising these was deemed to be the main barrier to diagnosing patients early.

20 Jan 2016

Estrogen helps women fight flu virus better than men

Estrogen dramatically reduced the amount of flu virus that replicated in infected cells from women but not from men, a new study by researchers at the Johns Hopkins Bloomberg School of Public Health shows.

20 Jan 2016

New technique may accelerate development of novel vaccines

An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.

20 Jan 2016

Women who carry inherited fault in BRIP1 gene at higher risk of developing ovarian cancer

Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a study published in the Journal of the National Cancer Institute.

20 Jan 2016

Hhex protein could be key target for new therapies to cure leukaemia

Melbourne researchers have showed that they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth.

20 Jan 2016

Rice scientists develop new tool to analyze thermal behaviors of DNA and RNA strands

Rice University scientists have developed a tool to speed the design of molecular diagnostics that depend on the specific recognition of pathogen DNA and RNA.

20 Jan 2016

New method could improve accurate diagnosis of ovarian cancer before surgery

In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99% of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers.

20 Jan 2016

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

19 Jan 2016

Bevacizumab extends survival of pleural mesothelioma patients

Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standard treatment according to phase III trial findings published in The Lancet.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

Common mortality causes prevail in epilepsy patients

A prospective, community-based study confirms that patients with epilepsy usually die of the same causes as other people.

19 Jan 2016

WASF3 protein appears to be solid target for reducing cancer metastasis

A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report.

19 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration is a condition of the macula, a tiny area of the retina at the back of the eye. Your macula is only about the size of the grain of rice, that’s about four millimeters across.

19 Jan 2016

Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

If you're scared of the dentist's needles you're not alone - but new research means you might not have to put off that appointment again. A study published in Colloids and Surfaces B: Biointerfaces reveals how the dentist could give you anesthetic using a tiny electric current instead of a needle.

19 Jan 2016

Phthalate DEHP could lead to weight gain

In cooperation with the Integrated Research and Treatment Center Adiposity Diseases at the University of Leipzig and the University Hospital Leipzig, researchers from the Helmholtz Centre for Environmental Research have now published a study in the PLOS ONE journal showing that the phthalate DEHP leads to weight gain and revealed the metabolic processes involved.

19 Jan 2016

Adaptive, light-activated nanotherapy effective against drug-resistant bacteria

In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.

19 Jan 2016

CRISPR/Cas9 gene editing technique could be controlled using RNA-based drugs

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, though, leading to risk of additional editing at unwanted sites.

19 Jan 2016